Aims: To examine biochemical effects of phosphate-containing replacement fluid (Phoxilium®) for continuous venovenous hemofiltration (CVVH). Methods: Retrospective comparison of respective serum biochemistry with sequential use of Accusol™ and Phoxilium, each over 48 h of CVVH. Results: We studied 15 critically ill patients. Accusol was switched to Phoxilium after 5 (4–8) days of CVVH. Respective serum biochemistry after 36–42 h of Accusol versus Phoxilium were: phosphate 1.02 (0.82–1.15) versus 1.44 (1.23–1.78) mmol/l, ionized calcium 1.28 (1.22–1.32) versus 1.12 (1.06–1.21) mmol/l, bicarbonate 24 (23–25) versus 20 (19–22) mmol/l, base excess 0 (–2 to 1) versus –4 (–6 to –3) mmol/l (p < 0.001). Cumulative phosphate intakes during respective periods were 69.6 (56.6–76.6) versus 67.2 (46.6–79.0) mmol (p = 0.45). Plasma strong ion differences were narrower with Phoxilium (p < 0.05), with similar strong ion gaps. No additional intravenous phosphate was given during Phoxilium use. Seven patients had serum phosphate >1.44 mmol/l. Conclusions: Phoxilium versus Accusol use during CVVH effectively prevented hypophosphatemia but contributed to mild hyperphosphatemia, and is associated with relative hypocalcemia and metabolic acidosis.

Keywords:
Phoxilium, Phosphate-containing solution, Accusol, Acute kidney injury, Continuous renal replacement therapy, Hyperphosphatemia, Hypophosphatemia, Hypocalcemia, Metabolic acidosis
1.
Geerse DA, Bindels AJ, Kuiper MA, Roos AN, Spronk PE, Schultz MJ: Treatment of hypophosphatemia in the intensive care unit: a review. Crit Care 2010;14:R147.
2.
Paleologos M, Stone E, Braude S: Persistent, progressive hypophosphataemia after voluntary hyperventilation. Clin Sci (Lond) 2000;98:619–625.
3.
Kjeldsen SE, Moan A, Petrin J, Weder AB, Julius S: Effects of increased arterial epinephrine on insulin, glucose and phosphate. Blood Press 1996;5:27–31.
4.
Marinella MA: Refeeding syndrome and hypophosphatemia. J Intens Care Med 2005;20:155–159.
5.
Loghmani S, Maracy MR, Kheirmand R: Serum phosphate level in burn patients. Burns 2010;36:1112–1115.
6.
Aibiki M, Kawaguchi S, Maekawa N: Reversible hypophosphatemia during moderate hypothermia therapy for brain-injured patients. Crit Care Med 2001;29:1726–1730.
7.
Palevsky PM, Zhang JH, O’Connor TZ, Chertow GM, Crowley ST, Choudhury D, Finkel K, Kellum JA, Paganini E, Schein RM, Smith MW, Swanson KM, Thompson BT, Vijayan A, Watnick S, Star RA, Peduzzi P: Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med 2008;359:7–20.
8.
Bellomo R, Cass A, Cole L, Finfer S, Gallagher M, Lo S, McArthur C, McGuinness S, Myburgh J, Norton R, Scheinkestel C, Su S: Intensity of continuous renal-replacement therapy in critically ill patients. N Engl J Med 2009;361:1627–1638.
9.
Demirjian S, Teo BW, Guzman JA, Heyka RJ, Paganini EP, Fissell WH, Schold JD, Schreiber MJ: Hypophosphatemia during continuous hemodialysis is associated with prolonged respiratory failure in patients with acute kidney injury. Nephrol Dial Transplant 2011;26:3508–3514.
10.
Cohen J, Kogan A, Sahar G, Lev S, Vidne B, Singer P: Hypophosphatemia following open heart surgery: Incidence and consequences. Eur J Cardiothorac Surg 2004;26:306–310.
11.
Schwartz A, Gurman G, Cohen G, Gilutz H, Brill S, Schily M, Gurevitch B, Shoenfeld Y: Association between hypophosphatemia and cardiac arrhythmias in the early stages of sepsis. Eur J Intern Med 2002;13:434.
12.
Shor R, Halabe A, Rishver S, Tilis Y, Matas Z, Fux A, Boaz M, Weinstein J: Severe hypophosphatemia in sepsis as a mortality predictor. Ann Clin Lab Sci 2006;36:67–72.
13.
Troyanov S, Geadah D, Ghannoum M, Cardinal J, Leblanc M: Phosphate addition to hemodiafiltration solutions during continuous renal replacement therapy. Intens Care Med 2004;30:1662–1665.
14.
Santiago MJ, Lopez-Herce J, Urbano J, Bellon JM, del Castillo J, Carrillo A: Hypophosphatemia and phosphate supplementation during continuous renal replacement therapy in children. Kidney Int 2009;75:312–316.
15.
Bollaert PE, Levy B, Nace L, Laterre PF, Larcan A: Hemodynamic and metabolic effects of rapid correction of hypophosphatemia in patients with septic shock. Chest 1995;107:1698–1701.
16.
Treger R, Pirouz S, Kamangar N, Corry D: Agreement between central venous and arterial blood gas measurements in the intensive care unit. Clin J Am Soc Nephrol 2010;5:390–394.
17.
Stewart PA: Modern quantitative acid-base chemistry. Can J Physiol Pharmacol 1983;61:1444–1461.
18.
Figge J, Mydosh T, Fencl V: Serum proteins and acid-base equilibria: a follow-up. J Lab Clin Med 1992;120:713–719.
19.
Spalding EM, Chamney PW, Farrington K: Phosphate kinetics during hemodialysis: Evidence for biphasic regulation. Kidney Int 2002;61:655–667.
20.
Ratanarat R, Brendolan A, Volker G, Bonello M, Salvatori G, Andrikos E, Yavuz A, Crepaldi C, Ronco C: Phosphate kinetics during different dialysis modalities. Blood Purif 2005;23:83–90.
21.
Broman M, Carlsson O, Friberg H, Wieslander A, Godaly G: Phosphate-containing dialysis solution prevents hypophosphatemia during continuous renal replacement therapy. Acta Anaesthesiol Scand 2011;55:39–45.
22.
Rennie MJ: Anabolic resistance in critically ill patients. Crit Care Med 2009;37:S398–S399.
23.
Santiago MJ, Lopez-Herce J, Munoz R, del Castillo J, Urbano J, Solana MJ, Botran M: Stability of continuous renal replacement therapy solutions after phosphate addition: an experimental study. Ther Apher Dial 2011;15:75–80.
24.
Morgera S, Heering P, Szentandrasi T, Manassa E, Heintzen M, Willers R, Passlick-Deetjen J, Grabensee B: Comparison of a lactate-versus acetate-based hemofiltration replacement fluid in patients with acute renal failure. Renal Failure 1997;19:155–164.
25.
Tan HK, Uchino S, Bellomo R: The acid-base effects of continuous hemofiltration with lactate or bicarbonate buffered replacement fluids. Int J Artif Organs 2003;26:477–483.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.